Status:
COMPLETED
Comparison Between Symbicort® and Prednisolone in COPD
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
To assess if Symbicort forte Turbuhaler (during two weeks) is as effective as an oral course of prednisolone + Oxis Turbuhaler (during two weeks) for the treatment of an acute exacerbation of Chronic ...
Eligibility Criteria
Inclusion
- Patients with chronic obstructive pulmonary disease and an acute exacerbation
- After the acute treatment a simple pulmonary function test shows a value of 30%-60% of the predicted normal value.
- Patients, who, based on the clinical examination after the initial acute treatment, are candidates for a course of oral steroids for the treatment of acute symptoms due to chronic obstructive pulmonary disease
Exclusion
- Diagnosis/history of asthma
- Oxygen uptake (saturation) is \<92% after the initial acute treatment
- A requirement for regular use of oxygen therapy
- Regular treatment with any inhaled steroid \>1 000 µg/day at study entry
- Additional inclusion and exclusion criteria will be evaluated by the investigator
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00259779
Start Date
September 1 2005
End Date
July 1 2007
Last Update
January 24 2011
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aalborg, Denmark
2
Research Site
Ålbæk, Denmark
3
Research Site
Christiansfeld, Denmark
4
Research Site
Erfurt, Denmark